Biotech Essentials

Career and Jobs

Biotech Career and Jobs Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 25.02.2021.

#biotechnology
#biospace
#lifesciences
#pharmaceuticals
#moversandshakers

Career And Jobs

@Biotechnology shared
On Feb 19, 2021
Project Farma: Manufacturing Skills Gap Creates Bottleneck for Cell and Gene Therapy https://t.co/5NZ5ht8YpW https://t.co/7K9qdT9uqr
Open
Project Farma: Manufacturing Skills Gap Creates Bottleneck for Cell and Gene Therapy

Project Farma: Manufacturing Skills Gap Creates Bottleneck for Cell and Gene Therapy

The skills gap in cell and gene therapy is creating a bottleneck that is slowing the abilities of innovative therapies to reach patients, delaying manufacturing scaleup and increasing ...

@Biotechnology shared
On Feb 22, 2021
AMR Action Fund Taps Henry Skinner to Lead, Secures New Investment Dollars https://t.co/QzAijYE36N https://t.co/sQjxuiy3pd
Open
AMR Action Fund Taps Henry Skinner to Lead, Secures New Investment Dollars

AMR Action Fund Taps Henry Skinner to Lead, Secures New Investment Dollars

The AMR Action Fund is ramping up its infrastructure – announcing yesterday that former Novartis Venture Funds Head, Henry Skinner, will take the helm as the organization’s first chief ...

@Biotechnology shared
On Feb 19, 2021
BioSpace Movers & Shakers, Feb. 19 https://t.co/lLAL9eaVFO https://t.co/KmCV5NDqKg
Open
BioSpace Movers & Shakers, Feb. 19

BioSpace Movers & Shakers, Feb. 19

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

@CMichaelGibson shared
On Feb 24, 2021
In the biggest CRO takeover in years, Icon doles out $12B for PRA Health Sciences to focus on decentralized clinical work https://t.co/9fQlp6guJk
Open
In the biggest CRO takeover in years, Icon doles out $12B for PRA Health Sciences to focus on decentralized clinical work

In the biggest CRO takeover in years, Icon doles out $12B for PRA Health Sciences to focus on decentralized clinical work

Contract research M&A had a healthy run in recent years before recently petering out. But with the market ripe for a big buyout and the Covid-19 pandemic emphasizing the importance of ...

@JohnCendpts shared
On Feb 24, 2021
Then #2 from @ka_blankenship Japan's SoftBank plots billions in biotech investments in move that could keep the valuation flood rising — report https://t.co/A5yiA9siQZ
Open
Japan's SoftBank plots billions in biotech investments in move that could keep the valuation flood rising — report

Japan's SoftBank plots billions in biotech investments in move that could keep the valuation flood rising — report

The valuation crazy train in biotech continues to roll into the new year with more than a dozen companies taking a chance on Nasdaq and money flowing in from all sides. Now, a Japanese ...

@Pharmafocus shared
On Feb 24, 2021
RedHill Biopharma to expand COVID-19 opaganib trial to US https://t.co/OJNLcggTbf https://t.co/AuynLZpoxg
Open
RedHill Biopharma to expand COVID-19 opaganib trial to US

RedHill Biopharma to expand COVID-19 opaganib trial to US

Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.

@Biotechnology shared
On Feb 23, 2021
6 Tips for Advancing Your Career While Working from Home https://t.co/URXjJxda0V https://t.co/URca0LEYDk
Open
6 Tips for Advancing Your Career While Working from Home

6 Tips for Advancing Your Career While Working from Home

Your career shouldn’t have to stay in a holding pattern just because you’re not at the office.

@FierceBiotech shared
On Feb 25, 2021
Zaks “will be leaving the company in late September” after six years at the biotech. Moderna quietly announced his exit near the end of its financials this morning https://t.co/JHufTf4on2 $MRNA
Open
Moderna's CMO Zaks quits for 'next leg of his career' after swift move to commercial focus

Moderna's CMO Zaks quits for 'next leg of his career' after swift move to commercial focus

As Moderna ramps up its COVID-19 vaccine efforts and has made one of the speediest moves from a hyped-up preclinical biotech to a commercial entity hoping to help save the world, its chief ...